Climb Bio, Inc. (CLYM)
NASDAQ: CLYM · Real-Time Price · USD
9.26
-0.24 (-2.53%)
At close: Apr 28, 2026, 4:00 PM EDT
9.33
+0.07 (0.76%)
After-hours: Apr 28, 2026, 6:59 PM EDT
Climb Bio Stock Forecast
Stock Price Forecast
The 11 analysts that cover Climb Bio stock have a consensus rating of "Strong Buy" and an average price target of $16.82, which forecasts a 81.64% increase in the stock price over the next year. The lowest target is $8.00 and the highest is $26.
Price Target: $16.82 (+81.64%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Climb Bio stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 3 | 3 | 3 | 6 | 6 |
| Buy | 3 | 3 | 3 | 4 | 5 | 6 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 6 | 6 | 7 | 11 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy Maintains $10 → $18 | Buy | Maintains | $10 → $18 | +94.38% | Apr 21, 2026 |
| Mizuho | Mizuho | Buy Initiates $18 | Buy | Initiates | $18 | +94.38% | Apr 15, 2026 |
| BTIG | BTIG | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | -13.61% | Apr 8, 2026 |
| B. Riley Securities | B. Riley Securities | Strong Buy Initiates $26 | Strong Buy | Initiates | $26 | +180.78% | Mar 24, 2026 |
| Truist Securities | Truist Securities | Strong Buy Initiates $17 | Strong Buy | Initiates | $17 | +83.59% | Mar 18, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.10
from -0.90
EPS Next Year
-1.28
from -1.10
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||||
| Avg | n/a | n/a | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -0.98 | -1.17 | ||||||
| Avg | -1.10 | -1.28 | ||||||
| Low | -1.18 | -1.48 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.